Ibex Medical Analytics and UPMC Join Forces for Advancing AI-based Prostate Cancer Diagnostics

24 Jul, 2018

Back

TEL AVIV, Israel, July 24, 2018 /PRNewswire/ — Ibex Medical Analytics, a pioneering developer of AI-powered cancer diagnostics, is announcing today its research collaboration with UPMC and digital pathology expert Dr. Liron Pantanowitz, Professor of Pathology and Biomedical Informatics and Vice Chairman of Pathology Informatics at UPMC Shadyside.

In this collaboration, UPMC and Ibex will apply the Ibex Second Read™ (SR) system on prostate core needle biopsies (PCNBs) from UPMC to further validate the performance characteristics of the AI-driven system in prostate cancer diagnosis.

The Ibex SR system has recently been announced as the first AI-driven diagnostic application in pathology to be applied in a clinical setting. It is deployed in the pathology institute of Maccabi Healthcare Services, one of the largest healthcare providers in Israel and Ibex’s strategic partner.

„The advent of digital pathology enables the implementation of AI-driven technologies to ensure more accurate and rapid cancer diagnosis in pathology institutes. We believe that systems such as the one developed by Ibex have an important role in advancing routine anatomic pathology practice. We will be assessing the performance of the Ibex Second Read system to determine its potential for implementation at UPMC,“ stated Dr. Pantanowitz.

„We are excited to be collaborating with UPMC, a world-renowned center for cancer diagnostics. This collaboration will enable us to further demonstrate our system’s validity and is a significant milestone in our journey to make pathology labs more accurate and efficient, leveraging cutting edge big data and machine learning technology,“ said Joseph Mossel, CEO of Ibex Medical Analytics.

Back

About IBEX

IBEX is the leader in AI-powered cancer diagnostics in pathology. We empower physicians to provide every patient with an accurate, timely and personalized cancer diagnosis. Our Galen™ platform is deployed worldwide, supporting pathologists and providers with AI-insights that help improve the quality and accuracy of diagnosis, reduce turnaround times and boost productivity.

By providing my details I agree to the IBEX-AI Terms and conditions and Privacy policy. I also agree to receive emails form IBEX-AI and I understand that I may opt out of IBEX-AI subscriptions at any time.

About IBEX

IBEX is the leader in AI-powered cancer diagnostics in pathology. We empower physicians to provide every patient with an accurate, timely and personalized cancer diagnosis. Our Galen™ platform is deployed worldwide, supporting pathologists and providers with AI-insights that help improve the quality and accuracy of diagnosis, reduce turnaround times and boost productivity.

By providing my details I agree to the IBEX-AI Terms and conditions and Privacy policy. I also agree to receive emails form IBEX-AI and I understand that I may opt out of IBEX-AI subscriptions at any time.